20 April 2012

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Publication of Annual Report and Notice of AGM

EKF Diagnostics Holdings plc (AIM: EKF), a growing business within the in-vitro diagnostic devices market, announces that that the Annual Report and Accounts for the year ended 31 December 2011, the Notice of the Annual General Meeting and a Form of Proxy have been published today on the Company's website: www.ekfdiagnostics.com. These documents will be posted to shareholders shortly.

The Company's Annual General Meeting will be held on Wednesday 23 May 2012 at 11am at the offices of Canaccord Genuity Limited, 88 Wood Street, London, EC2V 7QR.

Enquiries:

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2. 

For more information please visit the website: www.ekfdiagnostics.co.uk